Immunome Stock Surges on Positive Clinical Trial Results
Immunome shares rose 48% in three months after Phase 3 trial results for desmoid tumor drug Varegacestat showed 84% reduced progression risk. FDA approval sought in 2026.
Topic
Latest reporting and analysis tagged with clinical trial.
Immunome shares rose 48% in three months after Phase 3 trial results for desmoid tumor drug Varegacestat showed 84% reduced progression risk. FDA approval sought in 2026.
Goldman Sachs upgraded Crinetics Pharmaceuticals to Buy after trial data showed a 67% reduction in A4 for CAH. Citizens also reported positive early experience with Palsonify, supporting Q4 revenue.
Structure Therapeutics shares have risen over 130% in three months after reporting positive clinical trial results for its oral obesity pill, with analysts maintaining bullish ratings.
Eli Lilly's Taltz and Zepbound show superior efficacy in a Phase 3b trial for psoriatic arthritis and obesity. The company also agreed to acquire Ventyx Biosciences for about $1.2 billion.